Business · National
Vanguards of Healthcare: Senseonics Extends CGM Life to a Year
“We have the best-in-class accuracy, especially at the low end for predicting hypoglycemia, which is really important because of that light generation,” says Senseonics CEO Tim Goodnow, explaining the company’s implantable Eversense continuous glucose monitor (CGM) to Bloomberg Intelligence. Goodnow...
Verified Timeline
No verified timeline updates.
What is your view on “Vanguards of Healthcare: Senseonics Extends CGM Life to a Year”?
This is self-selected reader participation, not representative scientific polling.

